In some cell lines, the involvement of MAPK, mTOR, and PI3K/AKT pathways in the action of angelicin casts some light not only on its apoptotic effect but also indicates the compound's ability to interfere with the survival of cancer cells through other mechanisms. The gene discussed is AKT1; the disease is cancer.